Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Oral Doses of BI 1595043 in Healthy Men
NCT04439838Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1595043 in Crohn's disease and inflammatory bowel disease (IBD) (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events (AEs) up to 15 days. Started Aug 2020; status: completed.
02
Drugs
BI 1595043
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04439838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439838.